An evaluation of pitavastatin for the treatment of hypercholesterolemia

Paul Chan, Li Shao, Brian Tomlinson, Yuzhen Zhang, Zhong Min Liu

Research output: Contribution to journalArticle

Abstract

Introduction: Statins are the first line of therapy to reduce low-density lipoprotein cholesterol (LDL-C) in order to decrease cardiovascular events. Pitavastatin is the latest statin to be introduced to the market. Areas covered: In this article, the authors review the efficacy, safety, and tolerability of pitavastatin. The authors also review a recent cardiovascular outcome study. Expert opinion: Pitavastatin produces dose-dependent reductions in LDL-C at lower doses than other statins. The maximum approved dose of 4 mg reduces LDL-C by about 40–49% in different patient groups and is equivalent to atorvastatin 20 mg in this effect. Pitavastatin undergoes minimal metabolism so drug–drug interactions are less likely than with many other statins, but it can interact with some drugs that inhibit drug transporters. Compared with other statins, it has been associated with greater increases in high-density lipoprotein cholesterol and it was found to be less likely to cause new onset diabetes. In a recent study in Japanese patients with stable coronary artery disease, pitavastatin 4 mg was more effective than pitavastatin 1 mg in reducing cardiovascular events. Therefore, the highest dose may be preferred in high-risk patients.

Original languageEnglish
Pages (from-to)103-113
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
LDL Cholesterol
Therapeutics
Expert Testimony
Pharmaceutical Preparations
HDL Cholesterol
pitavastatin
Coronary Artery Disease
Outcome Assessment (Health Care)
Safety

Keywords

  • Hypercholesterolemia
  • pharmacodynamics
  • pharmacokinetics
  • pitavastatin
  • statins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

An evaluation of pitavastatin for the treatment of hypercholesterolemia. / Chan, Paul; Shao, Li; Tomlinson, Brian; Zhang, Yuzhen; Liu, Zhong Min.

In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 1, 02.01.2019, p. 103-113.

Research output: Contribution to journalArticle

Chan, Paul ; Shao, Li ; Tomlinson, Brian ; Zhang, Yuzhen ; Liu, Zhong Min. / An evaluation of pitavastatin for the treatment of hypercholesterolemia. In: Expert Opinion on Pharmacotherapy. 2019 ; Vol. 20, No. 1. pp. 103-113.
@article{308ca523d6de454fb5933ca2c88c153e,
title = "An evaluation of pitavastatin for the treatment of hypercholesterolemia",
abstract = "Introduction: Statins are the first line of therapy to reduce low-density lipoprotein cholesterol (LDL-C) in order to decrease cardiovascular events. Pitavastatin is the latest statin to be introduced to the market. Areas covered: In this article, the authors review the efficacy, safety, and tolerability of pitavastatin. The authors also review a recent cardiovascular outcome study. Expert opinion: Pitavastatin produces dose-dependent reductions in LDL-C at lower doses than other statins. The maximum approved dose of 4 mg reduces LDL-C by about 40–49{\%} in different patient groups and is equivalent to atorvastatin 20 mg in this effect. Pitavastatin undergoes minimal metabolism so drug–drug interactions are less likely than with many other statins, but it can interact with some drugs that inhibit drug transporters. Compared with other statins, it has been associated with greater increases in high-density lipoprotein cholesterol and it was found to be less likely to cause new onset diabetes. In a recent study in Japanese patients with stable coronary artery disease, pitavastatin 4 mg was more effective than pitavastatin 1 mg in reducing cardiovascular events. Therefore, the highest dose may be preferred in high-risk patients.",
keywords = "Hypercholesterolemia, pharmacodynamics, pharmacokinetics, pitavastatin, statins",
author = "Paul Chan and Li Shao and Brian Tomlinson and Yuzhen Zhang and Liu, {Zhong Min}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14656566.2018.1544243",
language = "English",
volume = "20",
pages = "103--113",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - An evaluation of pitavastatin for the treatment of hypercholesterolemia

AU - Chan, Paul

AU - Shao, Li

AU - Tomlinson, Brian

AU - Zhang, Yuzhen

AU - Liu, Zhong Min

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Statins are the first line of therapy to reduce low-density lipoprotein cholesterol (LDL-C) in order to decrease cardiovascular events. Pitavastatin is the latest statin to be introduced to the market. Areas covered: In this article, the authors review the efficacy, safety, and tolerability of pitavastatin. The authors also review a recent cardiovascular outcome study. Expert opinion: Pitavastatin produces dose-dependent reductions in LDL-C at lower doses than other statins. The maximum approved dose of 4 mg reduces LDL-C by about 40–49% in different patient groups and is equivalent to atorvastatin 20 mg in this effect. Pitavastatin undergoes minimal metabolism so drug–drug interactions are less likely than with many other statins, but it can interact with some drugs that inhibit drug transporters. Compared with other statins, it has been associated with greater increases in high-density lipoprotein cholesterol and it was found to be less likely to cause new onset diabetes. In a recent study in Japanese patients with stable coronary artery disease, pitavastatin 4 mg was more effective than pitavastatin 1 mg in reducing cardiovascular events. Therefore, the highest dose may be preferred in high-risk patients.

AB - Introduction: Statins are the first line of therapy to reduce low-density lipoprotein cholesterol (LDL-C) in order to decrease cardiovascular events. Pitavastatin is the latest statin to be introduced to the market. Areas covered: In this article, the authors review the efficacy, safety, and tolerability of pitavastatin. The authors also review a recent cardiovascular outcome study. Expert opinion: Pitavastatin produces dose-dependent reductions in LDL-C at lower doses than other statins. The maximum approved dose of 4 mg reduces LDL-C by about 40–49% in different patient groups and is equivalent to atorvastatin 20 mg in this effect. Pitavastatin undergoes minimal metabolism so drug–drug interactions are less likely than with many other statins, but it can interact with some drugs that inhibit drug transporters. Compared with other statins, it has been associated with greater increases in high-density lipoprotein cholesterol and it was found to be less likely to cause new onset diabetes. In a recent study in Japanese patients with stable coronary artery disease, pitavastatin 4 mg was more effective than pitavastatin 1 mg in reducing cardiovascular events. Therefore, the highest dose may be preferred in high-risk patients.

KW - Hypercholesterolemia

KW - pharmacodynamics

KW - pharmacokinetics

KW - pitavastatin

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85057858329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057858329&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1544243

DO - 10.1080/14656566.2018.1544243

M3 - Article

VL - 20

SP - 103

EP - 113

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -